The results of the TROPiCS-04 study compared Trodelvy (sacituzumab govitecan) to chemotherapy as second-line treatment for patients with locally advanced or metastatic UC previously treated with ...

Trodelvy (sacituzumab govitecan) has been approved for locally advanced or metastatic urothelial cancer, following a platinum-containing chemotherapy and PD-1/PD-L1 inhibitor immunotherapy.

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) recently approved a new targeted chemotherapy drug for ...

Gilead reports Q4 earnings on Feb. 11. Analysts expect $1.70 EPS. The LEO Pharma deal could reduce 2025 EPS by up to $0.17.

Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not include the cancer drug Trodelvy (sacituzumab govitecan-hziy) in the country’s standard package of ...

unlike conventional chemotherapy. Gilead's (GILD.O), opens new tab Trodelvy also belongs to the same class of drugs. AstraZeneca and Daiichi's first co-developed ADC, Enhertu, was first approved ...

Trodelvy’s nod in the disease mandates that ... for Datroway’s investigational combination with AZ’s Imfinzi and chemo could read out first-line NSCLC data this year. Following TROPION ...

Study participants were randomly assigned to receive the study drug or chemotherapy ... s Phase 3 results are comparable to those of Trodelvy, a TROP2-targeting ADC marketed by Gilead Sciences ...

Trodelvy has become the second ADC to pass the review after the breast cancer treatment 'Enhertu' developed by the British company AstraZeneca and the Japanese company Daiichi Sankyo. Having ...